<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01329913</url>
  </required_header>
  <id_info>
    <org_study_id>6325-003</org_study_id>
    <secondary_id>2010-023687-40</secondary_id>
    <nct_id>NCT01329913</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)</brief_title>
  <official_title>A Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-6325 in Hepatitis C Infected Male and Female Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2 part study of the safety, pharmacokinetics and pharmacodynamics of MK-6325 in&#xD;
      HCV-infected participants. Part I of the study will be for Genotype (GT) 1 HCV-infected&#xD;
      participants who will be randomized to receive either MK-6325 or placebo. If the drug is&#xD;
      shown to be safe and efficacious in Part I, Part II will enroll GT 3 HCV-infected&#xD;
      participants who will be randomized to receive either MK-6325 or placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing clinical and laboratory adverse events (AEs) (Parts I and II)</measure>
    <time_frame>Up to 15 days after last dose of study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral load reduction in GT1 HCV-infected participants (Part I)</measure>
    <time_frame>7 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load reduction in GT3 HCV-infected participants (Part II)</measure>
    <time_frame>7 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>GT1-HCV 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GT1-HCV 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GTI-HCV 800 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GT3-HCV 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GT3-HCV 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GT3-HCV 800 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-6325</intervention_name>
    <description>Two 100 mg capsules, orally, once per day for 7 days</description>
    <arm_group_label>GT1-HCV 200 mg</arm_group_label>
    <arm_group_label>GT3-HCV 200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to MK-6325</intervention_name>
    <description>Two 100 mg capsules, orally, once per day for 7 days</description>
    <arm_group_label>GT1-HCV 200 mg</arm_group_label>
    <arm_group_label>GT3-HCV 200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-6325</intervention_name>
    <description>Four 100 mg capsules, orally, once per day for 7 days</description>
    <arm_group_label>GT1-HCV 400 mg</arm_group_label>
    <arm_group_label>GT3-HCV 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to MK-6325</intervention_name>
    <description>Four 100 mg capsules, orally, once per day for 7 days</description>
    <arm_group_label>GT1-HCV 400 mg</arm_group_label>
    <arm_group_label>GT3-HCV 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-6325</intervention_name>
    <description>Eight 100 mg capsules, orally, once per day for 7 days</description>
    <arm_group_label>GT3-HCV 800 mg</arm_group_label>
    <arm_group_label>GTI-HCV 800 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to MK-6325</intervention_name>
    <description>Eight 100 mg capsules, orally, once per day for 7 days</description>
    <arm_group_label>GT3-HCV 800 mg</arm_group_label>
    <arm_group_label>GTI-HCV 800 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Body mass index (BMI) of 18 to ≤37 kg/m^2.&#xD;
&#xD;
          -  Stable health&#xD;
&#xD;
          -  No clinically significant abnormality on electrocardiogram (ECG)&#xD;
&#xD;
          -  Clinical diagnosis of chronic HCV infection (G1 or G3) for at least 6 months and&#xD;
             detectable HCV RNA in peripheral blood.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Pregnancy or intention to become pregnant or father a child during the course of the&#xD;
             study.&#xD;
&#xD;
          -  History of stroke, chronic seizures, major neurological disorder, or uncontrolled&#xD;
             clinically significant psychiatric disorder (for example, depression).&#xD;
&#xD;
          -  Estimated creatinine clearance of ≤70 mL/min.&#xD;
&#xD;
          -  History of clinically significant endocrine, gastrointestinal (except HCV infection),&#xD;
             cardiovascular, hematological, immunological, renal, respiratory, or genitourinary&#xD;
             abnormalities or diseases whose current condition is considered clinically unstable.&#xD;
&#xD;
          -  History of neoplastic disease other than adequately treated non-melanomatous skin&#xD;
             carcinoma or carcinoma in situ of the cervix ≥10 years prior to the prestudy&#xD;
             (screening) visit with no evidence of recurrence of likelihood of recurrence.&#xD;
&#xD;
          -  Positive Hepatitis B surface antigen at the pre-study (screening) visit.&#xD;
&#xD;
          -  History of documented HIV infection or positive HIV serology at the pre-study&#xD;
             (screening) visit.&#xD;
&#xD;
          -  Regular consumption of excessive amounts of alcohol, defined as greater than 2 glasses&#xD;
             of alcoholic beverages (1 glass is approximately equivalent to: beer [284 mL/10&#xD;
             ounces], wine [125 mL/4 ounces], or distilled spirits [25 mL/1 ounce]) per day.&#xD;
&#xD;
          -  Excessive consumption, defined as greater than 6 servings (1 serving is approximately&#xD;
             equivalent to 120 mg of caffeine) or coffee, tea, cola, or other caffeinated beverages&#xD;
             per day.&#xD;
&#xD;
          -  Major surgery, or donation or loss of 1 unit of blood (approximately 500 mL) or&#xD;
             participated in another investigational study within 4 weeks prior to the prestudy&#xD;
             (screening) visit.&#xD;
&#xD;
          -  History of significant multiple and/or severe allergies (including latex allergy), or&#xD;
             has had an anaphylactic reaction or significant intolerability to prescription or&#xD;
             non-prescription drugs or food.&#xD;
&#xD;
          -  Regular use of (including &quot;recreational use&quot;) of any illicit drugs or has a history of&#xD;
             drug (including alcohol) abuse within approximately 2 months. Exception: marijuana use&#xD;
             is permitted at the discretion of the investigator and provided the participant can&#xD;
             refrain from its use during the study.&#xD;
&#xD;
          -  Evidence or history of chronic hepatitis not caused by HCV including but not limited&#xD;
             to non-HCV viral hepatitis, non-alcoholic steatohepatitis (NASH), drug-induced&#xD;
             hepatitis, autoimmune hepatitis. Note: Participants with history of acute&#xD;
             non-HCV-related hepatitis, which resolved &gt;6 months before study can be enrolled.&#xD;
&#xD;
          -  Previous treatment with other HCV protease inhibitors ≤3 months prior to the first&#xD;
             dose of study drug.&#xD;
&#xD;
          -  Previous exposure to interferon-alpha and/or ribavirin within 3 month prior to the&#xD;
             first dose of MK-6325 in the study.&#xD;
&#xD;
          -  Clinical or laboratory evidence of advanced or decompensated liver disease; evidence&#xD;
             of bridging fibrosis or higher grade fibrosis (Metavir score ≥3) from prior liver&#xD;
             biopsy. Note: liver biopsy is not required for entry into the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Germany</country>
    <country>Moldova, Republic of</country>
  </removed_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>April 4, 2011</study_first_submitted>
  <study_first_submitted_qc>April 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2011</study_first_posted>
  <last_update_submitted>February 4, 2015</last_update_submitted>
  <last_update_submitted_qc>February 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

